REGN - Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

REGN

Regeneron Pharmaceuticals develops and commercializes medicines for various diseases, including eye disorders, allergic conditions, cancer, and rare diseases. Major products include EYLEA, Dupixent, Libtayo, and Praluent, targeting serious health issues.

⚕️ Healthcare NASDAQ Listed 1991 $ USD
$1,000 invested 30 years ago →$50,223today

Score Overview

1 Year
Score
Net Growth6.94%
Net TrendGrew
Net Income Consistency—
Rev Growth17.80%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.8
Net Growth-40.34%
Net Trend60%
Net Income Consistency—
Rev Growth5.13%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth437.94%
Net Trend70%
Net Income Consistency
Rev Growth247.63%
Rev Trend90%
Revenue Consistency
20 Years
Score7.9
Net Growth49x
Net Trend60%
Net Income Consistency
Rev Growth266x
Rev Trend90%
Revenue Consistency
30 Years
Score
Net Growth150x
Net Trend53%
Net Income Consistency
Rev Growth701x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth1072x
Net Trend51%
Net Income Consistency
Rev Growth2314x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Regeneron Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • REGN

2002: 97.7% · 2021: 7.5% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 957.76—
1 Year2025-11-17
$ 700.7236.68%
5 Years2021-11-17
$ 635.8350.63%
10 Years2016-11-17
$ 400.78138.98%
20 Years2006-11-17
$ 23.4340x
30 Years1996-11-15
$ 19.0750x
All Time1991-04-02
$ 20.9345x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 16.89B$ 4.81B$ 9.30B
2025$ 14.34B$ 4.50B$ 8.60B
2024$ 14.20B$ 4.41B$ 9.01B
2023$ 13.11B$ 3.95B$ 10.84B
2022$ 12.17B$ 4.33B$ 7.74B
2021$ 16.07B$ 8.07B$ 5.69B
2020$ 8.49B$ 3.51B$ 6.72B
2019$ 7.86B$ 2.11B$ 3.21B
2018$ 6.71B$ 2.44B$ 4.56B
2017$ 5.87B$ 1.19B$ 2.89B
2016$ 4.86B$ 895M$ 1.03B
2015$ 4.10B$ 636M$ 1.67B
2014$ 2.81B$ 348M$ 1.36B
2013$ 2.10B$ 424M$ 693M
2012$ 1.37B$ 750M$ 308M
2011$ 445M-$ 221M$ 526M
2010$ 459M-$ 104M$ 249M
2009$ 379M-$ 67M$ 341M
2008$ 238M-$ 82M$ 474M
2007$ 125M-$ 105M$ 766M
2006$ 63M-$ 102M$ 459M
2005$ 66M-$ 95M$ 298M
2004$ 174M$ 41M$ 295M
2003$ 57M-$ 107M$ 293M
2002$ 21M-$ 124M$ 264M
2001$ 21M-$ 76M$ 385M
2000$ 59M-$ 23M$ 117M
1999$ 34M-$ 23M$ 66M
1998$ 38M-$ 8M$ 19M
1997$ 33M-$ 11M$ 28M
1996$ 24M-$ 32M$ 34M
1995$ 27M-$ 23M$ 32M
1994$ 23M-$ 30M$ 23M
1993$ 10M-$ 39M$ 12M
1992$ 11M-$ 19M$ 16M
IPO1991$ 7M-$ 4M$ 26M
REGN - Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 4.10B to $ 14.34B and net income grew from $ 636M to $ 4.50B. Revenue increased in 9 of those 10 years; net income in 7.

Between 2005 and 2025, revenue grew from $ 66M to $ 14.34B and net income went from -$ 95M to $ 4.50B. Revenue increased in 18 of those 20 years; net income in 12.

Regeneron Pharmaceuticals Inc currently holds a 20-year HDB Score of 7.9 out of 10. How the HDB Score is calculated.

Membership

Continue REGN’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies